🇺🇸 L-leucine in United States

22 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dehydration — 4 reports (18.18%)
  2. Abdominal Discomfort — 2 reports (9.09%)
  3. Acquired Haemophilia — 2 reports (9.09%)
  4. Acute Kidney Injury — 2 reports (9.09%)
  5. Alopecia — 2 reports (9.09%)
  6. Anaemia — 2 reports (9.09%)
  7. Chronic Kidney Disease — 2 reports (9.09%)
  8. Cough — 2 reports (9.09%)
  9. Decreased Appetite — 2 reports (9.09%)
  10. Hepatocellular Carcinoma — 2 reports (9.09%)

Source database →

L-leucine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is L-leucine approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for L-leucine in United States?

Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache is the originator. The local marketing authorisation holder may differ — check the official source linked above.